prostatic carcinoma

Long-term side effect of orchiectomy in treatment of prostatic carcinoma.

Survival of the patient with prostatic carcinoma is related to the extent of the tumor.

On his routine annual examination, a small and localized recurrence of prostatic carcinoma was detected.

Phase II evaluation of coumarin (1,2-benzopyrone) in metastatic prostatic carcinoma.

JTB has also been implicated in prostatic carcinomas.

(2) Known or possible androgen-dependent tumors for example male breast carcinoma or prostatic carcinoma.

Gleason DF: Histologic grading and clinical staging of prostatic carcinoma.

Hinman F Jr: Screening for prostatic carcinoma.

Millikan RE: Chemotherapy of advanced prostatic carcinoma.

This includes multiple human tumor cell lines including glioblastoma, melanoma, ovarian carcinoma, prostatic carcinoma, and breast carcinomas).

Finally, an 80 year old man with a history of myocardial infarction, rheumatoid arthritis, and metastatic prostatic carcinoma presented with abdominal pain four months after the procedure.

Waterhouse RL, Resnick MI: The use of transrectal prostatic ultrasonography in the evaluation of patients with prostatic carcinoma.

Karling P, Hammar M, Varenhorst E: Prevalence and duration of hot flushes after surgical or medical castration in men with prostatic carcinoma.

Mutations in the IL-6 promoter region may play a role in the tumorigenic effects of constitutive IL-6 expression in prostatic carcinoma cells [ 33 ] .

Brawer MK, Chetner MP, Beatie J, et al.: Screening for prostatic carcinoma with prostate specific antigen.

Wallner K, Roy J, Harrison L: Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma.

Peeling WB: Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma.

The ability of screening for prostatic carcinoma by determining levels of prostate-specific antigen or for lung cancer by spiral computer-automated tomography to save lives has not, in fact, been proved.

Crawford ED, Eisenberger MA, McLeod DG, et al.: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.

Soloway MS, Schellhammer PF, Smith JA, et al.: Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II multicenter trial.

Epstein JI, Paull G, Eggleston JC, et al.: Prognosis of untreated stage A1 prostatic carcinoma: a study of 94 cases with extended followup.

Zelefsky MJ, Whitmore WF Jr, Leibel SA, et al.: Impact of transurethral resection on the long-term outcome of patients with prostatic carcinoma.

Further investigation into androgen-induced changes in gene and protein expression in vitro and in vivo will undoubtedly shed light on prostatic physiology and prostatic carcinoma, and also on broader physiological functions of androgen.

Kaisary AV, Tyrrell CJ, Peeling WB, et al.: Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma.

Reports on this have been published for prostatic carcinoma, where thymidine kinase has been suggested as a supplement to PSA (Prostate Specific Antigen), the tumor marker now most frequently used in prostate cancer.